+

US20030083345A1 - Method of treatment and/or prevention of brain, spinal or nerve injury - Google Patents

Method of treatment and/or prevention of brain, spinal or nerve injury Download PDF

Info

Publication number
US20030083345A1
US20030083345A1 US10/187,587 US18758702A US2003083345A1 US 20030083345 A1 US20030083345 A1 US 20030083345A1 US 18758702 A US18758702 A US 18758702A US 2003083345 A1 US2003083345 A1 US 2003083345A1
Authority
US
United States
Prior art keywords
methyl
trifluoromethyl
bis
tolyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/187,587
Other languages
English (en)
Inventor
Torsten Hoffmann
Alan Nimmo
Andrew Sleight
Pierre Vankan
Robert Vink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VINK, ROBERT, NIMMO, ALAN, HOFFMANN, TORSTEN, SLEIGHT, ANDREW, VANKAN, PIERRE
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Publication of US20030083345A1 publication Critical patent/US20030083345A1/en
Priority to US11/481,216 priority Critical patent/US20060247240A1/en
Priority to US12/886,691 priority patent/US20110053954A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is generally related to NK-1 receptor antagonists and more particularly to the administration of NK-1 receptor antagonists in a method of treatment and/or prevention of brain, spinal or nerve injury.
  • Brain, spinal or nerve injury occurs in connection with accidents and results often in the development of motor and cognitive deficits that contribute to the significant morbidity experienced by survivors of accidents. Due to their life style younger members of the society are particularly prone to such accidents. The financial loss caused by the injuries incurred by such accidents is significant. Therefore, any means to increase the survival and an improved recovery of nerve damages incurred in accidents is of great benefit to society.
  • Neurokinin-1 or substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue.
  • the receptor for neurokinin-1 or substance P is a member of the superfamily of G protein-coupled receptors and is named NK-1 receptor. This receptor is widely distributed throughout the mammalian nervous system (especially brain and spinal ganglia) and is also present in the circulatory system and in peripheral tissues (especially the duodenum, the jejunum and the genito-urinary tract). The receptor is believed to be involved in the regulation of a number of diverse biological processes as outlined below.
  • the central and peripheral actions of the mammalian tachykinin substance P have been associated with numerous inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's disease (Neurosci. Res., 7, 187-214, (1996)), anxiety (Can. J. Phys., 75, 612-621, (1997)) and depression (Science, 281, 1640-1645, (1998)).
  • CNS central nervous system
  • neurokinin-1 receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinin, in particular substance P.
  • Examples of conditions in which substance P has been implicated include disorders of the central nervous system such as anxiety, depression and psychosis (International Patent Application, Publication Nos. WO 95/16679, WO 95/18124 and WO 95/23798).
  • neurokinin-1 receptor antagonists are further believed to be useful for the treatment of motion sickness and for treatment induced vomiting.
  • U.S. Pat. No. 5,972,938 describes a method for treating a psychoimmunologic or a psychosomatic disorder by administration of a tachykinin receptor, such as the NK-1 receptor antagonist.
  • European Patent Application EP-A-721 778 relates to the use of a specific group of compounds in the manufacture of a medicament for the treatment of a disorder selected from stroke, epilepsy head trauma, spinal cord trauma, ischemic neuronal damage from stroke or vascular occlusion, excitoxic neuronal damage and amyotrophic sclerosis in a mammal.
  • a method of treatment or prevention of brain, spinal or nerve injury comprising administering to a patient in need of such treatment a therapeutically effective amount of the selective, brain penetrant NK-1 receptor antagonist of the formula
  • R 1 is hydrogen or halogen
  • R 2 and R 2′ are, independently from each other, selected from the group consisting of hydrogen, halogen, trifluoromethyl, lower alkyl, lower alkoxy and cyano; or
  • R 4 is selected from the group consisting of hydrogen, —N(R 5 ) 2 , —N(R 5 )(CH 2 ) n OH, —N(R 5 )S(O) 2 -lower alkyl, —N(R 5 )S(O) 2 -phenyl, —N ⁇ CH—N(R 5 ) 2 , —N(R 5 )C(O)R 5 , a cyclic tertiary amine of the group
  • R 4 is —(C ⁇ C) m R 7 or —(CR′ ⁇ CR′′) m R 7
  • R′/R′′ are independently from each other selected from the group consisting of hydrogen, hydroxy, lower alkyl, cycloalkyl
  • heteroaryl group containing one to four heteroatoms, selected from the group consisting of N, O and S
  • R 9 is selected from the group consisting of hydrogen, lower alkyl, trifluoromethyl, aryl, substituted lower alkyl and substituted aryl, said lower alkyl and aryl being substituted by by one or more substituents, selected from
  • R 10 is —C(O)—(CH 2 ) m OH or an oxo group
  • R 4 is an N-oxide of the formula
  • R 13 is hydrogen, hydroxy, lower alkyl, lower alkoxy, —(CH 2 ) p OH, —COOR 3 , —CON(R 3 ) 2 , —N(R 3 )CO-lower alkyl or —C(O)R 3 ;
  • R 6 is hydrogen, hydroxy, lower alkyl, —(CH 2 ) n COO-lower alkyl, —N(R 5 )CO-lower alkyl, hydroxy-lower alkyl, cyano, —(CH 2 ) n O(CH 2 ) n OH, —CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group;
  • X is —C(O)N(R 5 )—, —(CH 2 ) m O—, —O(CH 2 ) m —, —(CH 2 ) m N(R 5 )—, —N(R 5 )C(O)—, or —N(R 5 )(CH 2 ) m —;
  • m is 1 or 2;
  • the present invention also relates to the use of an NK-1 receptor antagonist of the formula (I) for the manufacture of a pharmaceutical composition for the treatment and/or prevention of brain, spinal or nerve injury.
  • the invention also relates to a method of treatment and/or prevention of brain, spinal or nerve injury in a mammal, including a human, by administering an effective amount of an NK-1 receptor antagonist of the formula (I) and a pharmaceutically acceptable excipient.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one or more NK-1 receptor antagonists and a pharmaceutically acceptable excipient for the treatment and/or prevention of brain, spinal or nerve injury.
  • the NK-1 receptor antagonist may be present in the form of a pharmaceutically acceptable acid addition salt or may be present in the form of a prodrug, preferably in the form of an N-oxide.
  • EP-A-1,035,115 also provides proposals for suitable formulations of NK-1 receptor antagonists, which are also suitable for the method of treatment of the present invention.
  • the neuroprotective action of NK-1 receptor antagonists can be enhanced with the addition of pharmacologic doses of magnesium to the i.v. solution. Therefore, in an embodiment of the invention, the NK-1 receptor antagonist as used in accordance with the present invention, such as N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide, is preferably co-administered with pharmacologic doses of magnesium salts (10-100 mg/kg) in order to enhance the neuroprotective properties
  • FIG. 3 shows the reduced Evans Blue penetration in animals treated with the NK-1 receptor antagonist compared to animals treated with either saline or MK801 after traumatic brain injury.
  • NK-1 receptor antagonist refers to a 100-fold to 10,000-fold higher affinity of the antagonist to the NK-1 receptor compared to its affinity to either the NK-2 receptor and/or the NK-3 receptor.
  • brain penetrant in the phrase refers to the fact that the NK-1 receptor antagonists used in accordance with the present invention show a good brain penetration, viz. are able to cross the blood-brain barrier (BBB). This is in contrast to N-acetyl-L-tryptophan which shows only a very reduced brain penetration.
  • BBB blood-brain barrier
  • the preferred compounds used in accordance with the present invention display both superior anxiolytic and antidepressive activity and are also able to cross the BBB.
  • the animals treated with the preferred compounds in the treatment and/or for the prevention of brain, spinal or nerve injury show therefore also a markedly reduced post-traumatic depression.
  • cyclic tertiary amine denotes, for example, pyrrolidin-1-yl, imidazol-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1-oxo-thiomorpholin-4-yl, 1,1-dioxo-thiomorpholin-4-yl, 2,3-dihydro-[1,4]oxazin-4-yl, or [1,2,4]triazol-1-yl.
  • heteroaryl group containing one to four heteroatoms, selected from N, O or S
  • pyrrol-1-yl imidazol-1 or 2-yl, pyrazol-1-yl, pyridin-2, 3 or 4-yl, pyrazinyl, pyrimidinyl, pyridazinyl, isothiazolyl, isoxazolyl, thienyl, 1,2,3-triazolyl, 1,2,4-oxadiazolyl, tetrahydro-pyridinyl, isoxazolyl or furyl.
  • the term “five or six membered saturated cyclic tertiary amine” denotes, for example, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiomorpholin-1,1-dioxo or thiomorpholin-1-oxo.
  • 5 or 6 membered heterocyclic group denotes, for example pyridinyl, pyrimidinyl, oxadiazolyl, triazolyl, tetrazolyl, thiazolyl, thienyl, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, piperazinyl or piperidyl.
  • aryl denotes a monocyclic aromatic hydrocarbon radical or a bicyclic or tricyclic ring system in which at least one ring is aromatic, preferred are phenyl, benzyl or naphthyl rings.
  • pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
  • a pharmacologic dose of magnesium means a dosage of a magnesium provided by any suitable means such as by adding a non-toxic magnesium salt such as magnesium chloride, magnesium sulfate, magnesium oxalate, magnesium gluconate, etc., whereby the magnesium is administered to the patient either seperately or in combination with the NK-1 receptor antagonist.
  • the dosage of the magnesium administered is in the range of 0.1 to 30 mg/kg body weight.
  • Preferred compounds for the claimed use are the exemplary compounds in which X in formula (I) is —C(O)N(R 5 )— and wherein R 5 is methyl, ethyl or cyclopropyl, for example the following compounds:
  • EP-A-1,035,115 also provides values for the affinity of selected compounds to the NK-1 receptor, given as pKi, whereby the pKi value for preferred compounds is in the range of 8.00 to 9.80.
  • EP-A-1,035,115 also provides proposals for suitable formulations of NK-1 receptor antagonists, which are also suitable for the method of treatment of the present invention.
  • the most preferred compound for the use in accordance with the present invention is N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide disclosed in EP-A-1,035,115.
  • R 4 is —(C ⁇ C) m R 7 or —(CR′ ⁇ CR′′) m R 7 .
  • Typical compounds in this group can be characterized as follows:
  • Compounds of formula (I), in which X is —C(O)N(CH 3 )— and —(R 2 ) n is 3,5-di-CF 3 represent a first group of compounds.
  • Exemplary preferred compounds of this group are those, wherein R 3 /R 3 are both hydrogen and R is methyl, for example the following compounds:
  • R 4 is —(C ⁇ C) m R 7 or —(CR′ ⁇ CR′′) m R 7 and in which X is —N(CH 3 )C(O)— and —(R 2 ) n is 3,5-di-CF 3 .
  • Exemparly preferred compounds of this group are those, wherein R 3 /R 3 are both methyl and R is methyl, for example the following compounds:
  • NK-1 receptor antagonist in accordance with the use of the present invention may be present in the form of a prodrug.
  • Preferred prodrugs of the compounds of formula (I) are N-oxides such as the following exemplary compounds:
  • N-oxide prodrug of formula (I) for the claimed method of treatment is 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-oxy-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide.
  • NK-1 receptor antagonist for use in connection with the claimed invention may be administered either alone or in combination with other therapeutic agents and are preferably formulated to a pharmaceutical composition comprising pharmaceutically acceptable carriers or diluents.
  • the pharmaceutical preparations to be used in accordance with this invention can in addition also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants.
  • NK-1 receptor antagonists can be formulated in the form of a Self-Emulsifying Drug Delivery Systems (SEDDS), which consist of mixtures of oils and surfactants, ideally isotropic, which sometimes include co-solvents.
  • SEDDS Self-Emulsifying Drug Delivery Systems
  • Such mixtures emulsify under conditions of gentle agitation, similar to those which would be encountered in the gastro intestinal tract.
  • SEDDS When such a formulation is released into the lumen of the gut, it disperses to form a fine emulsion, so that the drug contained in the emulsion remains in solution in the gut, avoiding the dissolution step which frequently limits the rate of absorption of hydrophobic drugs from the crystalline state.
  • SEDDS lead to improved bioavailability and/or a more consistent temporal profile of absorption from the gut. SEDDS have been described by Pouton C. W., in Advanced Drug Delivery Reviews, 25, (1997), 47-58.
  • the NK-1 receptor antagonist or the pharmaceutical composition comprising it is preferably administered intravenously.
  • An injection solution may have the following composition: Compound of formula (I) 1 mg 1 n HCl 20 ⁇ l acetic acid 0.5 mg NaCl 8 mg phenol 10 mg 1 n NaOH q.s. ad pH 5 H 2 O q.s. ad 1 ml
  • the NK-1 receptor antagonist or the pharmaceutical composition comprising it can also be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the NK-1 receptor antagonist or the pharmaceutically composition comprising it can also be administered via any other suitable way known to the person skilled in the art.
  • the dosage can vary within wide limits and can, of course, be fitted to the individual requirements in each particular case.
  • the dosage range for a beneficial effect in mammals depends of course on the activity of the NK-1 receptor antagonist that is used, but is usually in the range of 5 to 1000 mg/kg/d and is preferably between 25 and 100 mg/kg/d.
  • the pharmaceutical preparations in accordance with this invention can in addition also contain pharmaceutically inert, inorganic or organic excipients suitable for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts etc. can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
  • Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
  • Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
  • Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • NK-1 receptor antagonists in particular N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide, have the potential to reduce the development of motor and cognitive deficits followed after traumatic nerve injury and can therefore be used in the treatment and/or prevention of brain, spinal or nerve injury. While the following example illustrates the invention it is not meant to limit the scope of the claimed invention in any respect.
  • mice administered the NK-1 receptor antagonist N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide in accordance with the method of treatment of the invention demonstrated a significantly better motor outcome after brain injury than the animals treated with either saline or MK801 (FIG. 1).
  • the animals administered the NK-1 receptor antagonist N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide after traumatic brain injury in accordance with the method of treatment of the present invention did not demonstrate an increased latency to escape the aversive stimuli at any time point after brain injury. Indeed, their time to locate the escape tunnel after injury improved with each assessment (FIG. 2), suggesting that the NK-1 receptor antagonist of the method of treatment of the present invention was markedly protective against loss of cognitive function after traumatic brain injury.
  • the NK-1 receptor antagonist N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide also reduced mortality.
  • Mortality in rats in this severe model of injury is normally between 20 and 30%.
  • mortality was indeed 30%.
  • Administration of MK801 after trauma resulted in an increased mortality of 50%, averaging to a 40% mortality across these two injury groups. This high mortality was consistent with this injury level being severe as confirmed by post mortem gross histological analysis of all brains.
  • Mortality after trauma may be related to edema formation, particularly in children where profound edema has been shown to account for up to 50% of all deaths.
  • Edema formation in the immediate post-traumatic period is thought to be vasogenic in origin, where increased permeability of the blood brain barrier permits protein extravasation and water accumulation in the brain interstitium.
  • Evans Blue extravasation as a marker of blood brain permeability after traumatic brain injury and treatment with the NK-1 receptor antagonist N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide.
  • mice treated in accordance with the method of the present invention with the NK-1 receptor antagonist N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide had a significantly reduced Evans Blue penetration (18%) indicating that the compound had markedly attenuated post-traumatic blood brain barrier permeability and associated edema formation (FIG. 3).
  • NK-1 receptor antagonist N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide had a number of general effects on the animals that was beneficial to their outcome.
  • animals displayed a more stable respiratory pattern than their saline and MK801 treated counterparts.
  • animals treated in accordance with the method of treatment of the present invention with the NK-1 receptor antagonist compound were able to be weaned off of the ventilator far more quickly than any other treatment group after brain injury.
  • NK-1 receptor antagonist N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide in accordance with the method of treatment of the present invention may also be therapeutically effective for attenuating post-traumatic depression following brain injury.
  • the NK-1 receptor antagonist as used in accordance with the present invention such as N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide, is preferably co-administered with pharmacologic doses of magnesium salts (10-100 mg/kg) in order to enhance the neuroprotective properties.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
US10/187,587 2001-07-10 2002-07-02 Method of treatment and/or prevention of brain, spinal or nerve injury Abandoned US20030083345A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/481,216 US20060247240A1 (en) 2001-07-10 2006-07-05 Method of treatment and/or prevention of brain, spinal or nerve injury
US12/886,691 US20110053954A1 (en) 2001-07-10 2010-09-21 Method of treatment and/or prevention of brain, spinal or nerve injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01116812.7 2001-07-10
EP01116812 2001-07-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/481,216 Continuation US20060247240A1 (en) 2001-07-10 2006-07-05 Method of treatment and/or prevention of brain, spinal or nerve injury

Publications (1)

Publication Number Publication Date
US20030083345A1 true US20030083345A1 (en) 2003-05-01

Family

ID=8178001

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/187,587 Abandoned US20030083345A1 (en) 2001-07-10 2002-07-02 Method of treatment and/or prevention of brain, spinal or nerve injury
US11/481,216 Abandoned US20060247240A1 (en) 2001-07-10 2006-07-05 Method of treatment and/or prevention of brain, spinal or nerve injury
US12/886,691 Abandoned US20110053954A1 (en) 2001-07-10 2010-09-21 Method of treatment and/or prevention of brain, spinal or nerve injury

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/481,216 Abandoned US20060247240A1 (en) 2001-07-10 2006-07-05 Method of treatment and/or prevention of brain, spinal or nerve injury
US12/886,691 Abandoned US20110053954A1 (en) 2001-07-10 2010-09-21 Method of treatment and/or prevention of brain, spinal or nerve injury

Country Status (24)

Country Link
US (3) US20030083345A1 (fr)
EP (2) EP1621195A3 (fr)
JP (1) JP2004536119A (fr)
KR (1) KR100589106B1 (fr)
CN (1) CN100346789C (fr)
AR (1) AR037008A1 (fr)
AU (1) AU2002328837B2 (fr)
BR (1) BR0210893A (fr)
CA (1) CA2451566C (fr)
GT (1) GT200200143A (fr)
HK (1) HK1068266A1 (fr)
HR (1) HRP20031071A2 (fr)
HU (1) HUP0401210A3 (fr)
IL (1) IL159350A0 (fr)
MX (1) MXPA04000278A (fr)
NO (1) NO332847B1 (fr)
NZ (1) NZ530107A (fr)
PA (1) PA8549901A1 (fr)
PE (1) PE20030238A1 (fr)
PL (1) PL211246B1 (fr)
RU (1) RU2304435C2 (fr)
UY (1) UY27374A1 (fr)
WO (1) WO2003006016A2 (fr)
ZA (1) ZA200400138B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090533A1 (en) * 2003-07-03 2005-04-28 Torsten Hoffmann Dual NK1/NK3 receptor antagonists
US6897226B2 (en) * 2000-07-14 2005-05-24 Hoffmann-La Roche Inc. NK-1 receptor active amine oxide prodrugs
WO2005107744A1 (fr) * 2004-05-07 2005-11-17 Roelants, Ivo Atteinte d'un nerf
US20060217393A1 (en) * 2005-03-23 2006-09-28 Christoph Funk NK-1 receptor antagonists
WO2015000033A1 (fr) * 2013-07-02 2015-01-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Procédé pour la prévention et/ou le traitement de l'encéphalopathie traumatique chronique-ii
WO2015000035A1 (fr) * 2013-07-02 2015-01-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Procédé de prévention et/ou traitement de l'encéphalopathie traumatique chronique-4
WO2015068744A1 (fr) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 Dérivé de carboxyméthylpipéridine
KR20170002474A (ko) 2014-05-07 2017-01-06 깃세이 야쿠힌 고교 가부시키가이샤 사이클로헥실피리딘 유도체

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005026669D1 (de) 2004-07-06 2011-04-14 Hoffmann La Roche Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
ATE441633T1 (de) * 2005-02-22 2009-09-15 Hoffmann La Roche Nk1-antagonisten
MX2007009571A (es) 2005-02-25 2007-09-21 Hoffmann La Roche Tabletas con dispersion mejorada de la sustancia del farmaco.
PT2774925T (pt) 2005-11-08 2017-04-04 Vertex Pharma Moduladores heterocíclicos de transportadores de cassete de ligação ao atp
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
EP2789606B1 (fr) 2007-05-09 2017-11-15 Vertex Pharmaceuticals Incorporated Modulateurs de CFTR
AU2008278273A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
KR20150066608A (ko) 2007-12-07 2015-06-16 버텍스 파마슈티칼스 인코포레이티드 사이클로알킬카복시아미도-피리딘 벤조산의 제조 방법
RS55559B1 (sr) 2007-12-07 2017-05-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
NZ703814A (en) 2008-02-28 2016-06-24 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
CN105451727B (zh) * 2013-07-02 2019-04-23 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 用于预防和/或治疗i型慢性创伤性脑病的方法
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
MX381732B (es) 2014-11-18 2025-03-13 Vertex Pharma Proceso para efectuar la prueba de alto rendimiento de la cromatografia liquida de alta resolucion.
CA3089662A1 (fr) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Formulations parenterales et leurs utilisations
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
US20230124548A1 (en) * 2019-08-23 2023-04-20 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic Methods And Uses Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376507B1 (en) * 1994-12-12 2002-04-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of neuronal injury and stroke
US6841551B2 (en) * 2000-01-18 2005-01-11 Hoffmann-La Roche Inc. Brain, spinal, and nerve injury treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5607947A (en) * 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
JP2002506459A (ja) * 1997-06-27 2002-02-26 メルク シヤープ エンド ドーム リミテツド 置換された３−（ベンジルアミノ）ピペリジン誘導体およびその治療薬としての使用
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
KR100437587B1 (ko) * 1999-02-24 2004-06-30 에프. 호프만-라 로슈 아게 3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도
SI1035115T1 (en) * 1999-02-24 2005-02-28 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376507B1 (en) * 1994-12-12 2002-04-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of neuronal injury and stroke
US6841551B2 (en) * 2000-01-18 2005-01-11 Hoffmann-La Roche Inc. Brain, spinal, and nerve injury treatment

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897226B2 (en) * 2000-07-14 2005-05-24 Hoffmann-La Roche Inc. NK-1 receptor active amine oxide prodrugs
US20050090533A1 (en) * 2003-07-03 2005-04-28 Torsten Hoffmann Dual NK1/NK3 receptor antagonists
CN1852712B (zh) * 2003-07-03 2010-06-09 弗·哈夫曼-拉罗切有限公司 用于治疗精神分裂症的双重nk1/nk3拮抗剂
WO2005107744A1 (fr) * 2004-05-07 2005-11-17 Roelants, Ivo Atteinte d'un nerf
US20060217393A1 (en) * 2005-03-23 2006-09-28 Christoph Funk NK-1 receptor antagonists
US7211579B2 (en) * 2005-03-23 2007-05-01 Hoffmann-La Roche Inc. NK-1 receptor antagonists
WO2015000033A1 (fr) * 2013-07-02 2015-01-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Procédé pour la prévention et/ou le traitement de l'encéphalopathie traumatique chronique-ii
WO2015000035A1 (fr) * 2013-07-02 2015-01-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Procédé de prévention et/ou traitement de l'encéphalopathie traumatique chronique-4
WO2015068744A1 (fr) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 Dérivé de carboxyméthylpipéridine
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
US10100030B2 (en) 2013-11-08 2018-10-16 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
KR20170002474A (ko) 2014-05-07 2017-01-06 깃세이 야쿠힌 고교 가부시키가이샤 사이클로헥실피리딘 유도체
US9708266B2 (en) 2014-05-07 2017-07-18 Kissei Pharmaceutical Co., Ltd. Cyclohexyl pyridine derivative
US10011568B2 (en) 2014-05-07 2018-07-03 Kissei Pharmaceutical Co., Ltd. Cyclohexyl pyridine derivative

Also Published As

Publication number Publication date
MXPA04000278A (es) 2004-05-04
EP1406618A2 (fr) 2004-04-14
NO20040057L (no) 2004-01-07
CN1523988A (zh) 2004-08-25
ZA200400138B (en) 2005-06-29
RU2304435C2 (ru) 2007-08-20
CA2451566C (fr) 2013-09-10
KR100589106B1 (ko) 2006-06-14
HK1068266A1 (en) 2005-04-29
US20110053954A1 (en) 2011-03-03
HUP0401210A3 (en) 2011-07-28
NZ530107A (en) 2006-01-27
HUP0401210A2 (hu) 2004-10-28
GT200200143A (es) 2002-11-11
PL211246B1 (pl) 2012-04-30
JP2004536119A (ja) 2004-12-02
PE20030238A1 (es) 2003-03-19
PA8549901A1 (es) 2003-01-24
CN100346789C (zh) 2007-11-07
WO2003006016A3 (fr) 2003-07-31
CA2451566A1 (fr) 2003-01-23
EP1621195A3 (fr) 2010-01-06
KR20040029362A (ko) 2004-04-06
HRP20031071A2 (en) 2004-06-30
RU2004102397A (ru) 2005-04-20
AU2002328837B2 (en) 2005-05-05
AR037008A1 (es) 2004-10-20
PL369535A1 (en) 2005-05-02
BR0210893A (pt) 2004-06-22
IL159350A0 (en) 2004-06-01
WO2003006016A2 (fr) 2003-01-23
NO332847B1 (no) 2013-01-21
EP1621195A2 (fr) 2006-02-01
UY27374A1 (es) 2003-03-31
US20060247240A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
US20060247240A1 (en) Method of treatment and/or prevention of brain, spinal or nerve injury
AU2002328837A1 (en) Use of NK-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
US10195213B2 (en) Chemical entities that kill senescent cells for use in treating age-related disease
TWI684450B (zh) 猝倒症之治療
AU2002250876B2 (en) Use of NK-1 receptor antagonists against benign prostatic hyperplasia
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
JP2002527392A (ja) 末梢的に作用する抗掻痒アヘン剤
AU2002250876A1 (en) Use of NK-1 receptor antagonists against benign prostatic hyperplasia
KR20120103557A (ko) 파킨슨씨병 치료용 조성물 및 치료방법
US20210130305A1 (en) Prophylactic or therapeutic agent for autism spectrum disorder
TWI303991B (en) Use of nk-1 receptor antagonists for the treatment of brain,spinal or nerve injury
TW201808285A (zh) 焦慮症處置用組成物及處置方法
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
WO2018197638A1 (fr) Nouvelle utilisation du (5r)-5-[5-[{2-[3,5-bis(trifluorométhyl)phényl]-2-méthylpropanoyl}(méthyl)amino]-4-(4-fluoro-2-méthylphényl)-2-pyridinyl]-2-méthyl-d-prolinamide
US20040006142A1 (en) Ocular tension depressor
KR20090114371A (ko) 다발성 경화증 치료제

Legal Events

Date Code Title Description
AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOFFMANN, TORSTEN;NIMMO, ALAN;SLEIGHT, ANDREW;AND OTHERS;REEL/FRAME:013763/0049;SIGNING DATES FROM 20020816 TO 20020906

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:013763/0168

Effective date: 20020918

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载